JP2008521426A5 - - Google Patents

Download PDF

Info

Publication number
JP2008521426A5
JP2008521426A5 JP2007543912A JP2007543912A JP2008521426A5 JP 2008521426 A5 JP2008521426 A5 JP 2008521426A5 JP 2007543912 A JP2007543912 A JP 2007543912A JP 2007543912 A JP2007543912 A JP 2007543912A JP 2008521426 A5 JP2008521426 A5 JP 2008521426A5
Authority
JP
Japan
Prior art keywords
seq
domain
plad
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007543912A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008521426A (ja
Filing date
Publication date
Priority claimed from PCT/GB2005/002163 external-priority patent/WO2005118642A2/en
Priority claimed from PCT/GB2005/004319 external-priority patent/WO2006051288A2/en
Application filed filed Critical
Priority claimed from PCT/GB2005/004603 external-priority patent/WO2006059110A2/en
Publication of JP2008521426A publication Critical patent/JP2008521426A/ja
Publication of JP2008521426A5 publication Critical patent/JP2008521426A5/ja
Pending legal-status Critical Current

Links

JP2007543912A 2004-12-02 2005-12-01 ドメイン抗体への複合体化により血清半減期が延長されたｐｌａｄドメインペプチド Pending JP2008521426A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US63236104P 2004-12-02 2004-12-02
PCT/GB2005/002163 WO2005118642A2 (en) 2004-06-01 2005-05-31 Bispecific fusion antibodies with enhanced serum half-life
PCT/GB2005/004319 WO2006051288A2 (en) 2004-11-10 2005-11-10 Ligands that enhance endogenous compounds
PCT/GB2005/004603 WO2006059110A2 (en) 2004-12-02 2005-12-01 Plad domain peptides with increased serum half life due to conjugation to domain antibodies

Publications (2)

Publication Number Publication Date
JP2008521426A JP2008521426A (ja) 2008-06-26
JP2008521426A5 true JP2008521426A5 (https=) 2008-12-11

Family

ID=38792261

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007543912A Pending JP2008521426A (ja) 2004-12-02 2005-12-01 ドメイン抗体への複合体化により血清半減期が延長されたｐｌａｄドメインペプチド

Country Status (14)

Country Link
US (1) US20090111745A1 (https=)
EP (1) EP2024396A2 (https=)
JP (1) JP2008521426A (https=)
KR (1) KR20070099584A (https=)
CN (1) CN101111522A (https=)
AU (1) AU2005311103A1 (https=)
BR (1) BRPI0518762A2 (https=)
CA (1) CA2589802A1 (https=)
IL (1) IL183451A0 (https=)
MX (1) MX2007006602A (https=)
NO (1) NO20072670L (https=)
RU (2) RU2007119989A (https=)
WO (1) WO2006059110A2 (https=)
ZA (3) ZA200704431B (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7148061B2 (en) 2000-02-11 2006-12-12 The United States Of America As Represented By The Department Of Health And Human Services Identification of a novel domain in the tumor necrosis factor receptor family that mediates pre-ligand receptor assembly and function
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
AU2006261824A1 (en) * 2005-06-24 2007-01-04 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, National Institutes Of Health Amelioration of inflammatory arthritis by targeting the pre-ligand assembly domain (PLAD) of tumor necrosis factor receptors
WO2007146163A2 (en) * 2006-06-09 2007-12-21 Welson Pharmaceuticals, Inc. Fc-fusion proteins with reduced fc-mediated effector activities
US8460647B2 (en) 2007-04-20 2013-06-11 Amgen Inc. Pre-ligand assembly domain of the IL-17 receptor
US20090136427A1 (en) * 2007-09-18 2009-05-28 La Jolla Institute For Allergy And Immunology LIGHT Inhibitors For Asthma, Lung and Airway Inflammation, Respiratory, Interstitial, Pulmonary and Fibrotic Disease Treatment
WO2009040562A1 (en) * 2007-09-26 2009-04-02 Ucb Pharma S.A. Dual specificity antibody fusions
SG173488A1 (en) 2009-02-19 2011-09-29 Glaxo Group Ltd Improved anti-serum albumin binding variants
EP2453920A2 (en) 2009-07-16 2012-05-23 Glaxo Group Limited Antagonists, uses & methods for partially inhibiting tnfr1
EP2523686A2 (en) 2010-01-14 2012-11-21 Glaxo Group Limited Liver targeting domain antibodies
CN103221422B (zh) 2010-07-29 2017-03-29 十一生物治疗股份有限公司 嵌合il‑1受体i型激动剂和拮抗剂
SMT201700185T1 (it) 2010-08-23 2017-05-08 Univ Texas Anticorpi anti-ox40 e metodi di uso degli stessi
RU2014107743A (ru) * 2011-07-29 2015-09-10 Илэвэн Байотерапьютикс, Инк. Очищенные белки
US20130129727A1 (en) * 2011-11-17 2013-05-23 Nanjingjinsirui Science & Technology Biology Corporation Methods and systems for increasing protein stability
US9273092B2 (en) 2011-12-23 2016-03-01 RioGin LLC Selective binding compounds
US20130165628A1 (en) * 2011-12-23 2013-06-27 Sri International Double Binding Constructs
SG10201707477SA (en) 2013-03-13 2017-10-30 Eleven Biotherapeutics Inc Chimeric cytokine formulations for ocular delivery
MX371328B (es) 2013-08-30 2020-01-27 Aprilbio Co Ltd Constructo de fusion de la fraccion efectora del fragmento de union a antigeno (fab) de anti-albumina de suero y su metodo de preparacion.
HRP20250319T1 (hr) * 2017-02-16 2025-05-09 Sonnet BioTherapeutics, Inc. Fuzijski proteini s domenom za vezanje na albumin
CN112409480B (zh) * 2019-08-20 2024-08-27 四川科伦博泰生物医药股份有限公司 结合血清白蛋白的蛋白及其用途
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
WO2023039583A1 (en) * 2021-09-10 2023-03-16 Trustees Of Tufts College Anti-pd-1 immunoglobulin polypeptides and uses thereof

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL83878A (en) * 1987-09-13 1995-07-31 Yeda Res & Dev Soluble protein corresponding to tnf inhibitory protein its preparation and pharmaceutical compositions containing it
US6479632B1 (en) * 1988-09-12 2002-11-12 Yeda Research And Development Co. Ltd. Tumor necrosis factor inhibitory protein and its purification
US5512544A (en) * 1987-09-13 1996-04-30 Yeda Research And Development Co. Ltd. Pharmaceutical compositions comprising an anticytokine
US5359037A (en) * 1988-09-12 1994-10-25 Yeda Research And Development Co. Ltd. Antibodies to TNF binding protein I
US5811261A (en) * 1988-09-12 1998-09-22 Yeda Research And Development Co. Ltd. Expression of the recombinant tumor necrosis factor binding protein I (TBP-I)
ATE289350T1 (de) * 1989-04-21 2005-03-15 Amgen Inc Tnf-rezeptor, tnf bindende proteine und dafür kodierende dnas
JPH03164179A (ja) * 1989-04-21 1991-07-16 Boehringer Ingelheim Internatl Gmbh Ｔｎｆレセプター、ｔｎｆ結合たん白質およびこれらをコードするｄｎａ
US6221675B1 (en) * 1989-04-21 2001-04-24 Amgen, Inc. TNF receptors, TNF binding proteins and DNAs coding for them
US7264944B1 (en) * 1989-04-21 2007-09-04 Amgen Inc. TNF receptors, TNF binding proteins and DNAs coding for them
US6262239B1 (en) * 1989-05-18 2001-07-17 Yeda Research And Development Co., Ltd. TNF receptor-specific antibodies
US6232446B1 (en) * 1989-05-18 2001-05-15 Yeda Research And Development Co. Ltd. TNF ligands
ES2072330T5 (es) * 1989-05-18 2013-06-24 Yeda Research And Development Co., Ltd. Proteínas de unión II al Factor de Necrosis Tumoral, su purificación y anticuerpos frente a los mismos
SE509359C2 (sv) * 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
US6242213B1 (en) * 1996-12-23 2001-06-05 Immunex Corporation Isolated DNA molecules encoding RANK-L
US6696545B1 (en) * 1997-04-11 2004-02-24 Sangstat Medical Corporation Cytomodulating lipophilic peptides for modulating immune system activity and inhibiting inflammation
EP2180054A1 (en) * 1999-12-24 2010-04-28 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
WO2001057219A2 (en) * 2000-02-02 2001-08-09 Schering Corporation Mammalian interleukin-1-delta and -epsilon. their use in therapeutic and diagnostic methods
US7148061B2 (en) * 2000-02-11 2006-12-12 The United States Of America As Represented By The Department Of Health And Human Services Identification of a novel domain in the tumor necrosis factor receptor family that mediates pre-ligand receptor assembly and function
DK1399484T3 (da) * 2001-06-28 2010-11-08 Domantis Ltd Dobbelt-specifik ligand og anvendelse af denne
JP2004537580A (ja) * 2001-08-10 2004-12-16 エピックス メディカル， インコーポレイテッド 延長された循環半減期を有するポリペプチド結合体
ES2263984T3 (es) * 2002-06-28 2006-12-16 Domantis Limited Ligandos doble-especificos con una vida media serica aumentada.
WO2004041867A2 (en) * 2002-11-08 2004-05-21 Ablynx N.V. Camelidae antibodies against imminoglobulin e and use thereof for the treatment of allergic disorders
CA2505316C (en) * 2002-11-08 2014-08-05 Ablynx N.V. Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
KR20070084069A (ko) * 2004-10-08 2007-08-24 도만티스 리미티드 Ｔｎｆｒ1에 대한 단일 도메인 항체 및 이의 사용 방법

Similar Documents

Publication Publication Date Title
JP2008521426A5 (https=)
RU2007119989A (ru) Композиции, слитые конструкции и конъюгаты plad домена
JP5199876B2 (ja) 一価ＩｇＧを生成するための方法
TWI608015B (zh) 具有組織標的功能的抗發炎分子
KR101281208B1 (ko) 피브로넥틴 ｅｄ-ｂ에 대한 항체 ｌ１９ 및 인터루킨１２의 융합 단백질
JP2008512988A5 (https=)
JP2019137675A5 (https=)
JP2015509097A5 (https=)
TWI886164B (zh) 1價ccap生成物之製造方法
JP2021502810A5 (https=)
JP2008543278A5 (https=)
JP2017529059A5 (https=)
JP2006511516A5 (https=)
JP2008508882A5 (https=)
JP2016524592A5 (https=)
JP2019507589A5 (https=)
JPH04507195A (ja) 腫瘍壊死因子結合リガンド
JP2010502208A (ja) 半減期の長い血清アルブミン結合タンパク質
JP2014519830A5 (https=)
JP2011521662A5 (https=)
JP2017529067A (ja) Ｃｄ３結合ドメイン
JP2009517069A5 (https=)
JP6469012B2 (ja) インターロイキン−６に対する抗体およびその使用
JP2010524849A5 (https=)
WO2019096026A1 (zh) 抗il-17抗体/tnfr ecd融合蛋白及其用途